



EDITORIAL

Proton pump inhibitors in the COVID-19 pandemic[☆]

Los inhibidores de la bomba de protones en la pandemia por la COVID-19

The 2018 annual report on the Sistema Nacional de Salud (SNS) [National Health System] by the Ministry of Health states that the chemical subgroup with the highest consumption by number of packages through medical prescriptions corresponds to the antiulcer agents, particularly the proton pump inhibitors (PPIs). Omeprazole is the drug of choice in this group and is the most widely used active ingredient, with 50 million packages sold, representing 5.3% of all medicinal products.¹

PPIs are also among the most widely used medicines in other European Union countries and in the United States, and they have been linked to a number of adverse side effects, such as bone fractures, chronic kidney disease, vitamin B deficiency¹² and gastrointestinal infections, among others.² However, not all the possible side effects and risks of the long-term use of PPIs reported are real. In some cases, such as their possible association with dementia, myocardial infarction or kidney disease, the studies in which they were reported could have had biases due to the failure to consider that patients who start PPIs have more comorbidities and are more polymedicated than patients who do not, which is particularly true of older adults. This, rather than the exposure to the actual PPIs, may account for the differences in the rates of certain adverse effects.³

Furthermore, a study carried out in 2019 by Vilcu et al.⁴ reported that the continuous use of PPIs is associated with an increased risk of viral infection during periods of high endemic prevalence, such as the one we are experiencing. This effect is probably related to the secondary hypochlorhydria induced by these drugs, which lowers the upper gastrointestinal tract's defences against ingested bacteria and viruses,² and the fact that long-term use of PPIs appears to reduce microbial diversity in the gut.⁵ This may all be relevant, since the SARS-CoV-2 virus can enter

the body not only through the respiratory system but also through the digestive tract.⁶

In this vein, Almario et al. recently published a controversial study in the *American Journal of Gastroenterology*, carried out via a self-administered *online* survey in the United States, which found that individuals who used PPIs at least once a day were significantly more likely to have test positive for COVID-19 ($aOR_{2,15}$; confidence interval (CI) 95%, 1.90–2.44 and $aOR_{3,67}$; CI 95%, 2.93–4.60, if they took them once or twice a day, respectively) compared to those not on PPIs. Individuals taking histamine-2 receptor antagonists (H_2 blockers) do not have an elevated risk.⁷

The actual authors acknowledge that the study has a number of limitations, apart from methodological shortcomings, hence the data should be approached with caution.

However, as the authors comment, the results of the study may constitute evidence of an *association* between the use of PPIs and the probability of testing positive for COVID-19, although this study does not provide evidence of *causality*, in the absence of a prospective clinical trial, and further investigation is called for in different populations and settings through specifically designed prospective randomised clinical trials.⁷

Other authors^{8,9} contribute data that patients with COVID-19 who were regularly treated with PPIs before hospitalisation had a significantly higher mortality rate than non-users and the consumption of these drugs was a negative predictive factor for the development of secondary diseases such as COVID-19.

Several letters were soon published^{10–12} in response to the Almario study on account of its methodological deficiencies and inconsistencies: this association lost its potency following correction for age and renal, pulmonary and cardiovascular comorbidities, which indicated that the effect of PPIs on mortality could be related to other factors associated with the use of PPIs and not the actual drug. These authors convey the concern that the data published could generate unnecessary anxiety among some patients and perhaps lead to the interruption of these drugs in those who need them for an adequate clinical indication, possi-

[☆] Please cite this article as: Sebastián Domingo JJ. Los inhibidores de la bomba de protones en la pandemia por la COVID-19. *Gastroenterol Hepatol.* 2021;44:611–613.

bly entailing a significant risk or harm to the patient if they are suspended.

Simultaneously to the aforementioned Almaro et al.⁷ study, Lee et al.¹³ conducted another study with a large Korean cohort of present and past PPI users. Among the patients with confirmed COVID-19, the *current use* of PPIs conferred a 79% higher risk of a serious clinical outcome (need for oxygen therapy, admission to the Intensive Care Unit (ICU), need for invasive ventilation or death), while the relationship with *previous use* of PPIs was insignificant. In turn, the current use of PPIs initiated in the previous 30 days was associated with a 90% greater risk of severe clinical evolution of COVID-19 (admission to the ICU, need for invasive ventilation or death).

In the same line, Li et al.¹⁴ performed their own meta-analysis on the subject, also underlining the fact that current or regular PPI users were more likely to have severe COVID-19 than non-PPI users, with a pooled odds ratio (OR) of 1.67 (95% CI: 1.19–2.33, $p=0.003$) and a pooled hazard ratio (HR) of 1.87 (95% CI: 1.29–2.70, $p<0.001$), emphasising that extreme caution should be exercised with patients receiving PPIs during this pandemic.

The results of the Lee et al.¹³ study were also conflicting, and the study was criticised for its limitations and methodological deficiencies, which also prompted letters of response. In this regard, Roulet¹⁵ also reports that the results should be interpreted with caution, since the patients in the current PPI use group were older and presented more comorbidities than those in the other groups, which could have caused some type of bias. In any case, they report that in patients most severely affected by COVID-19 who require treatment with a PPI in intensive care, it must be ensured that the proven benefits of such drugs outweigh the potential risks of using them. To date, the risks of these drugs are only hypothetical.

In January this year, Fan et al.¹⁶ published a study including 9469 participants who had been tested for COVID-19 in the UK Biobank, 16% of whom were regularly taking a gastric acid suppressant, PPI or H₂ blocker versus 84% who were not taking them.

For the study, 1516 users and 1516 non-users of gastric acid suppressants finally underwent a matched analysis. The characteristics of the participants in these two groups were well balanced.

Among the regular users of acid suppressants there was a higher proportion of patients aged <65 years and a higher prevalence of comorbidities compared to the non-users, thus reducing the confounding effects of the possible risk factors, biases, in the results.

The OR of testing positive for COVID-19 associated with PPI therapy or an H₂ blocker in the matched cohort was 1.08 (95% CI, 0.89–1.31) and 0.94 (95% CI, 0.65–1.38), respectively. On the other hand, in the analysis, neither the use of PPIs or H₂ blockers was associated with the risk of SARS-CoV-2 infection in patients with upper gastrointestinal tract diseases. However, they found that the use of omeprazole alone was significantly related to an increased risk of SARS-CoV-2 infection based on the subgroup analysis in patients with upper gastrointestinal diseases (OR, 1.35; 95% CI, 1.01–1.82), which was not observed with the use of other types of PPI. On the other hand, neither PPIs (HR, 0.80; CI 95%, 0.58–1.11) nor the use of H₂ blockers (HR, 1.18; CI 95%,

0.62–2.23) were associated with risk of death in COVID-19 patients in the matched cohort.

The obvious advantage of this latest study compared to the others is the detailed and validated information in a well-characterised cohort that includes the types of gastric acid suppressants used and the potential confounding risk factors, all of which affords it greater credibility.

In any case, when assessing the possible side effects of any drug, we should not forget that most of the associations reported in observational clinical research are false and that the minority of the associations that are true are usually exaggerated. This issue is especially problematic in the case of associations of RRs or ORs below 4, such as the studies that have been reviewed. These associations, commonly reported in the medical literature, are more likely to be attributable to a bias than to a causal association. All observational research has a bias. Generally speaking, unless the RRs of the cohort studies exceed 2 or 3, or the ORs of the case-control studies exceed 3 or 4, the associations in the observed observational research should not be considered credible.¹⁷

In any event, these authors are reminding physicians to regularly review the need for gastric acid suppression in all patients on PPIs: physicians must ensure that the expected benefits and the risks of PPI therapy are balanced and that the lowest and most effective dose is used for the shortest recommended duration.

In the light of all these studies on the possible effects of PPIs on the incidence and evolution of COVID-19, some studies have emerged^{18,19} on famotidine, an H₂ blocker, that seem to attribute a protective effect to it. Mather et al.¹⁸ report that the use of this preparation in *hospitalised patients* with COVID-19 is associated with a lower risk of mortality, a combined result of mortality and the need for tracheal intubation and with lower levels of serum markers of severe disease (CRP, ferritin, D-dimer) in hospitalised patients with COVID-19. Similarly, Janowitz et al.¹⁹ suggest that high-dose oral famotidine is well tolerated and is associated with improved outcomes and evolution as reported by *non-hospitalised* COVID-19 patients.

For the time being, there is no explanation, or none is known, for the possible protective mechanism of famotidine in a patient with COVID-19, although a prospective randomised clinical trial has already been sponsored for this purpose,²⁰ the results of which remain to be seen.

Funding

No funding was received for this study.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. [Prestación Farmacéutica en el Sistema Nacional de Salud. Informe Anual del Sistema Nacional de Salud; 2018. Available from: https://tinyurl.com/y6ft8vzp](https://tinyurl.com/y6ft8vzp). Date of publication in the Transparency Portal: 12 November 2020.

2. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. *Gastroenterology*. 2017;153:35–48.
3. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. *Gastroenterology*. 2017;152:706–15.
4. Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. *JAMA Netw Open*. 2019;2:e1916205.
5. Kanno T, Matsuki T, Oka M, Utsunomiya H, Inada K, Magari H, et al. Gastric acid reduction leads to an alteration in lower intestinal microflora. *Biochem Biophys Res Commun*. 2009;381:666–70.
6. Trottein F, Sokol H. Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection. *Cell Rep*. 2020;32:107915.
7. Almario CV, Chey WD, Brennan MR, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. *Am J Gastroenterol*. 2020;115:1707–15.
8. Luxenburger H, Sturm L, Biever P, Rieg S, Duerschmied D, Schultheiss M, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? *J Intern Med*. 2021;289:121–4.
9. Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. *Dig Liver Dis*. 2020;52:1410–2.
10. Hadi YB, Naqvi SF, Kupec JT. Risk of COVID-19 in patients taking proton pump inhibitors. *Am J Gastroenterol*. 2020;115:1919–20.
11. Hajifathalian K, Katz PO. Regarding “increased risk of COVID-19 in patients taking proton pump inhibitors”. *Am J Gastroenterol*. 2020;115:1918–9.
12. Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. *Am J Gastroenterol*. 2020;115:1918.
13. Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. *Gut*. 2021;70:76–84.
14. Li GF, An XX, Yu Y, Jiao LR, Canarutto D, Yu G, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. *Gut*. 2020, <http://dx.doi.org/10.1136/gutjnl-2020-323366>.
15. Roulet L. A nationwide cohort study with propensity score matching. *Gut*. 2020, <http://dx.doi.org/10.1136/gutjnl-2020-323098>.
16. Fan X, Liu Z, Miyata T, Dasarathy S, Rotroff DM, Wu X, et al. Effect of acid suppressants on the risk of COVID-19: a propensity score-matched study using UK Biobank. *Gastroenterology*. 2021;160, 455–8.e5.
17. Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. *Obstet Gynecol*. 2012;120:920–7.
18. Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. *Am J Gastroenterol*. 2020;115:1617–23.
19. Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. *Gut*. 2020;69:1592–7.
20. Samimaghani HR, Azad MH, Haddad M, Arabi M, Hooshyar D, Kazemi Jahromi M. The efficacy of famotidine in improvement of outcomes in hospitalized COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020;21:848.

Juan J. Sebastián Domingo
 Servicio de Aparato Digestivo, Hospital Royo Villanova,
 Zaragoza, Spain
 E-mail address: jjsebastian@salud.aragon.es